Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy

PACE - Pacing and Clinical Electrophysiology

Volumn 28, Issue 12, 2005, Pages 1354-1356

  Simon, Ron D B ^a   Crawford III, Fred A ^a   Spencer III, William H ^a   Gold, Michael R ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Clinical; Defibrillation; Electrophysiology; Hypertrophic cardiomyopathy; ICD; Ventricular tachycardia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ALCOHOL;

ADULT; ALCOHOL SEPTAL ABLATION; ANAMNESIS; ARTICLE; CASE REPORT; CATHETER ABLATION; CLINICAL FEATURE; DEFIBRILLATOR; ELECTROPHYSIOLOGY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; RARE DISEASE; REENTRY ARRHYTHMIA; SCAR; ELECTROCARDIOGRAPHY; HEART VENTRICLE SEPTUM; HYPERTROPHIC CARDIOMYOPATHY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE;

CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ELECTROCARDIOGRAPHY; ETHANOL; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TACHYCARDIA, VENTRICULAR;

EID: 33645092694     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2005.00278.x     Document Type: Article

References (11)

1. Bahl VK, Chandra S, Chopra AK. Septal coronary artery ablation for hypertrophic obstructive cardiomyopathy. Indian Heart J 1996 48 : 701 703.
2. Boltwood CM Jr., Chien W, Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 2004 351 : 1914 1915.
3. McGregor JB, Rahman A, Rosanio S, et al. Monomorphic ventricular tachycardia: A late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. Am J Med Sci 2004 328 : 185 188.
4. Berger MD, Waxman HL, Buxton AE, et al. Spontaneous compared with induced onset of sustained ventricular tachycardia. Circulation 1988 78 : 885 892.
5. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000 342 : 365 373.
6. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999 20 : 1342 1354.
7. Kazmierczak J, Kornacewicz-Jach Z, Kisly M, et al. Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 1998 80 : 257 262.
8. Shakespeare CF, Keeling PJ, Slade AK, et al. Arrhythmia and hypertrophic cardiomyopathy. Arch Mal Coeur Vaiss 1992 85 (Spec No 4) : 31 36.
9. Stevenson WG, Friedman PL, Sager PT, et al. Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping. J Am Coll Cardiol 1997 29 : 1180 1189.
10. Crawford FA III., Killip D, Franklin J, et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation. Circulation 2004 108 : IV386 387.
11. Gradel C, Jain D, Batsford WP, et al. Relationship of scar and ischemia to the results of programmed electrophysiological stimulation in patients with coronary artery disease. J Nucl Cardiol 1997 4 : 379 386.